RU58841 is used by some for hair loss when finasteride and minoxidil are ineffective. Users report mixed results, with some experiencing side effects like chest pain and mood changes.
The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.
Hair loss affects confidence, with discussions on treatments like finasteride, minoxidil, and RU58841. Emphasis is placed on self-acceptance and building confidence beyond appearance.
RU58841's side effects may be exaggerated due to anxiety, with some users experiencing no issues and others reporting symptoms like chest pain. RU58841, minoxidil, and finasteride are used for hair loss treatment, with varying individual reactions.
RU58841 powder from a lab supplier was tested at a free drug testing service. The discussion includes using Minoxidil and finasteride for hair loss treatment.
RU58841 is being discussed as a hair loss treatment without using finasteride or dutasteride. Users are sharing their experiences and success with RU58841 alone.
SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.
A group buy for products to treat hair loss, such as Minoxidil, Finasteride and RU58841. Participants are interested in adding more people before ordering the next order.
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. A user asks about alfatradiol's availability, public perception, and usage in Germany.
Rhamnose may promote hair growth and pigmentation, suggesting it as a potential hair loss treatment. The conversation discusses its potential alongside known treatments like Minoxidil, finasteride, and RU58841.
Whether using both Fluridil and Alfatradiol together could be more effective than either one alone as a hair loss treatment, given their different mechanisms of action.
The conversation is about hair loss treatments, specifically the anticipation for the release of a new treatment, GT20029, by 2028. Users are discussing their experiences with current treatments like finasteride and dutasteride, and the potential of future treatments, including FAK inhibitors and verteporfin trials.
RU58841 from Amazon is unreliable, with users reporting no benefits and side effects like eye swelling and chest pain. Rudirect is recommended for purchasing in Europe.
Gut microbiota significantly influences androgen metabolism, impacting hair loss treatments like finasteride. Probiotics, dietary changes, and fecal microbiota transplants may help manage DHT levels and improve hair health.
Comparing two upcoming topical hair loss treatments, Fluridil and Breezula, to determine which is most effective for treating hair loss, taking into consideration factors such as price, side effects, potential for hair growth, convenience of application, smell, greasiness, and styling after use.
User seeks participants for Verteporfin group buy. Verteporfin, FDA approved, may regenerate hair follicles and sweat glands through heavy microneedling.
The conversation discusses the application of RU58841 for hair loss, with the user applying 1.75 mg at 5% concentration for half an hour daily. The user mentions managing seborrheic dermatitis while using this treatment.
The conversation discusses RU58841, a compound for hair loss treatment, which was found to be effective in a 6-month trial but was not pursued due to financial issues or marketability concerns, not safety. Some users are considering crowdfunding to release the research data, while others discuss personal experiences and safety concerns with RU58841.
A user improved their hair loss from NW3+ to NW1.5 over three years using a regimen of dutasteride, finasteride, Nizoral, biotin, and collagen. They experienced some side effects and adjusted dosages over time, and noted additional benefits like better skin and muscle gain.
Folligenz liposomal minoxidil sulfate is being discussed for its effectiveness and cost, with users comparing it to regular minoxidil and tretinoin. One user found no difference with the 10% version and noted that a lower tretinoin percentage reduced side effects like skin peeling.
A 22-year-old is frustrated with friends and family's dismissive attitudes towards hair loss and finds support and hope in an online community. They have not yet treated their hair loss but are considering medications like minoxidil and finasteride.
The user has been using finasteride and minoxidil for hair loss but experienced worsening temple recession. They suspect they might be more sensitive to testosterone and are considering trying RU58841 or CB 03 01 as additional treatments.
The conversation is about a user considering joining a clinical study for Clascoterone (Breezula) after experiencing no results with topical finasteride and minoxidil, and side effects from oral finasteride. The user is seeking advice on clinical study participation and experiences.
Clascoterone 5% solution (Breezula) is a promising alternative for androgenetic alopecia, showing continued hair growth with consistent use and no significant side effects. It may be suitable for those who cannot tolerate finasteride or dutasteride, especially when trying to conceive.
Finasteride is key for hair regrowth, supported by oral/topical minoxidil, Folexin, Nizoral/Head & Shoulders, and vitamin D. No side effects experienced; early intervention and patience are crucial.
A user with diffuse hair loss after taking accutane, which might have triggered genetic predisposition to AGA; their experience taking finasteride and experiencing side effects of increased oil production, increased sex drive, worsening hair texture; they are considering zinc supplementation with finasteride or other treatments such as alfatradiol or spironolactone.
PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.